RLM Realm Thera.

TIDMPURI

RNS Number : 2395O

PuriCore Plc

09 October 2012

PuriCore plc

("PuriCore" or the "Company")

9(th) October 2012

PuriCore Signs Two Major US Deals

Combined FloraFresh and Sterilox Fresh Contracts Valued at Approximately $9 Million

PuriCore(LSE: PURI), the water-based clean technology company, today announces it has signed two new sales agreements valued at approximately $9 million with leading US supermarket retailers. The first of these contracts, expected to generate approximately $7 million over four years, has been agreed with an existing customer, a top-five US supermarket retailer, to implement and use PuriCore's new formulation of FloraFresh. FloraFresh will be used by the supermarket's floral departments to improve the quality and shelf-life of flowers.

PuriCore has also signed a new sales agreement, which is expected to generate revenues of approximately $2 million by the end of 2012.The agreement has been signed with a long-standing US regional supermarket customer for the purchase of Sterilox Fresh Systems. This retailer has used Sterilox Fresh for more than five years under lease agreements and will now purchase new systems under a capital sales agreement.

Michael Ashton, Executive Chairman, said:

"PuriCore has established itself as a major player in the supermarket retail industry, helping customers to reduce fresh produce waste whilst improving quality and safety standards. Such benefits translate into lower inventory costs and improved margins for customers in an industry where margin protection is of critical importance. We are confident we will see continued traction amongst leading floral retailers and that FloraFresh will become an important source of revenue as we focus on expanding the business in new and existing markets."

About Sterilox Fresh and FloraFresh

Thousands of leading US and Canadian retail supermarkets rely on Sterilox Fresh to extend shelf-life and to address cross-contamination for fresh produce. Sterilox Fresh Systems generate a natural food-safe sanitizer that kills harmful pathogens and spoilage organisms on contact to keep perishable products safer and fresher for longer. Sterilox provides labour and inventory shrink cost savings to leading national and regional supermarket retailers.

FloraFresh controls bacterial growth in floral water to keep floral buckets clean and flowers hydrated longer. It is highly effective at killing a broad range of bacteria, viruses, and spoilage organisms, including Pseudomonas, Botrytis (gray mold), and powdery mildew. The use of FloraFresh lowers inventory shrink by extending vase life and lowers labour cleaning costs.

About PuriCore

PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary solutions that protect people from the spread of infectious pathogens without causing harm to human health or the environment. The Company's products are used in a broad range of markets that depend upon effective pathogen control. PuriCore is the leading full provider of all products and services required for a safe, efficient, and compliant endoscope decontamination to protect patients in UK hospitals. The Company's products are the de facto standard for food safety in leading US supermarket chains. PuriCore also offers a breakthrough wound therapy solution to treat chronic and acute wounds including diabetic ulcers and burns. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK. To receive additional information on PuriCore, visitwww.puricore.com, which does not form part of this press release.

Enquiries:

 
 UK                         US 
 FTI Consulting             Sage Strategic Marketing 
 Susan Stuart               Jennifer Guinan 
 Victoria Foster Mitchell   +1 610.410.8111 
 +44 (0) 20 7831 3113 
 

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

This information is provided by RNS

The company news service from the London Stock Exchange

END

CNTEKLBBLBFEFBD

Realm Thera. (LSE:RLM)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024

Realm Thera. (LSE:RLM)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024